Lexaria Announces $5.9 Million Warrant Exercise at Reduced $12.92 Per Share Price
On September 7, 2026, Lexaria Bioscience Corp. agreed with holders of existing warrants covering 453,969 shares to exercise them immediately at a reduced $12.92 per share, for expected gross proceeds of about $5.9 million before fees and expenses. In return, the company will issue new unregistered Series A and Series B warrants, each covering 453,969 shares at $12.67, and must file a resale registration statement for the underlying shares. The cash is intended for working capital and general corporate purposes, but the reduced exercise price and new warrants add potential future share issuance for existing shareholders.
Key points
- Expected gross proceeds of about $5.9 million from the warrant exercises, before placement agent fees and offering expenses; closing expected September 9, 2026.
- Existing warrants issued in 2024 and 2025 had original exercise prices from $17.85 to $45.90 per share; holders exercised at $12.92.
- New Series A warrants (five-year term) and Series B warrants (18-month term) each cover 453,969 shares at $12.67 per share.
- H.C. Wainwright & Co. is placement agent, paid a fee of 7% of gross proceeds, and received warrants for 15,889 shares at $16.15.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 09, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.